| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A CRITICal period for chemoradiotherapy in gastric cancer
|
Leong, Trevor
|
|
2018
|
19 |
5 |
p. 581-583
|
artikel
|
| 2 |
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
|
Wrangle, John M
|
|
2018
|
19 |
5 |
p. 694-704
|
artikel
|
| 3 |
An active drug for TRK-positive paediatric solid tumours
|
Moreno, Lucas
|
|
2018
|
19 |
5 |
p. 594-595
|
artikel
|
| 4 |
Anti-PD-1 antibody treatment for melanoma
|
Ribas, Antoni
|
|
2018
|
19 |
5 |
p. e219
|
artikel
|
| 5 |
Anti-PD-1 antibody treatment for melanoma – Authors' reply
|
Beaver, Julia A
|
|
2018
|
19 |
5 |
p. e220
|
artikel
|
| 6 |
Austrian MPs vote against smoking ban
|
Burki, Talha Khan
|
|
2018
|
19 |
5 |
p. e234
|
artikel
|
| 7 |
Body-mass index and metastatic melanoma outcomes
|
Wen, Hui
|
|
2018
|
19 |
5 |
p. e223
|
artikel
|
| 8 |
Body-mass index and metastatic melanoma outcomes
|
Daly, Louise E
|
|
2018
|
19 |
5 |
p. e224
|
artikel
|
| 9 |
Body-mass index and metastatic melanoma outcomes
|
Nabi, Hermann
|
|
2018
|
19 |
5 |
p. e226
|
artikel
|
| 10 |
Body-mass index and metastatic melanoma outcomes
|
Lennon, Hannah
|
|
2018
|
19 |
5 |
p. e225
|
artikel
|
| 11 |
Body-mass index and metastatic melanoma outcomes – Authors' reply
|
McQuade, Jennifer L
|
|
2018
|
19 |
5 |
p. e227-e228
|
artikel
|
| 12 |
Changing the standard of care for treating melanoma brain metastases
|
Chapman, Paul B
|
|
2018
|
19 |
5 |
p. 589-591
|
artikel
|
| 13 |
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|
Cats, Annemieke
|
|
2018
|
19 |
5 |
p. 616-628
|
artikel
|
| 14 |
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
|
Long, Georgina V
|
|
2018
|
19 |
5 |
p. 672-681
|
artikel
|
| 15 |
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology
|
Bristow, Robert G
|
|
2018
|
19 |
5 |
p. e240-e251
|
artikel
|
| 16 |
Combining top-ranked immunotherapeutics in lung cancer
|
Rolfo, Christian
|
|
2018
|
19 |
5 |
p. 592-594
|
artikel
|
| 17 |
Correction to Lancet Oncol 2018; 19: 580–81
|
|
|
2018
|
19 |
5 |
p. e229
|
artikel
|
| 18 |
Correction to Lancet Oncol 2018; 19: 705–14
|
|
|
2018
|
19 |
5 |
p. e229
|
artikel
|
| 19 |
Does global oncology need artificial intelligence?
|
Gyawali, Bishal
|
|
2018
|
19 |
5 |
p. 599-600
|
artikel
|
| 20 |
Effect of early palliative care: complex intervention and complex results
|
Ishiki, Hiroto
|
|
2018
|
19 |
5 |
p. e221
|
artikel
|
| 21 |
Effect of early palliative care: complex intervention and complex results – Authors' reply
|
Vanbutsele, Gaëlle
|
|
2018
|
19 |
5 |
p. e222
|
artikel
|
| 22 |
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|
Dummer, Reinhard
|
|
2018
|
19 |
5 |
p. 603-615
|
artikel
|
| 23 |
Health care for cancer survivors in the USA
|
Das, Manjulika
|
|
2018
|
19 |
5 |
p. e235
|
artikel
|
| 24 |
Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada
|
Kluetz, Paul G
|
|
2018
|
19 |
5 |
p. e267-e274
|
artikel
|
| 25 |
Investigators' response
|
Nout, Remi A
|
|
2018
|
19 |
5 |
p. 602
|
artikel
|
| 26 |
Is there any interest in a new BRAF–MEK inhibitor combination in melanoma?
|
Grob, Jean Jacques
|
|
2018
|
19 |
5 |
p. 580-581
|
artikel
|
| 27 |
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
|
Laetsch, Theodore W
|
|
2018
|
19 |
5 |
p. 705-714
|
artikel
|
| 28 |
Lawsuit filed against FDA for not reviewing e-cigarettes
|
Venkatesan, Priya
|
|
2018
|
19 |
5 |
p. e237
|
artikel
|
| 29 |
Major health-care companies merge in the USA
|
Alcorn, Ted
|
|
2018
|
19 |
5 |
p. 598
|
artikel
|
| 30 |
Minimalism in oncology
|
The Lancet Oncology,
|
|
2018
|
19 |
5 |
p. 579
|
artikel
|
| 31 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer
|
Price, Timothy J
|
|
2018
|
19 |
5 |
p. 587-589
|
artikel
|
| 32 |
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
|
Xu, Rui-Hua
|
|
2018
|
19 |
5 |
p. 660-671
|
artikel
|
| 33 |
Next generation of cancer survivors—a GP perspective
|
Clarke, Sinead
|
|
2018
|
19 |
5 |
p. 601
|
artikel
|
| 34 |
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial
|
Gelderblom, Hans
|
|
2018
|
19 |
5 |
p. 639-648
|
artikel
|
| 35 |
Nilotinib in locally advanced pigmented villonodular synovitis: challenges of a new targeted therapy
|
Gouin, Francois
|
|
2018
|
19 |
5 |
p. 584-586
|
artikel
|
| 36 |
Nivolumab plus ipilimumab in advanced renal-cell carcinoma
|
Gunjur, Ashray
|
|
2018
|
19 |
5 |
p. e232
|
artikel
|
| 37 |
No impact of English national cancer policies on survival
|
Burki, Talha Khan
|
|
2018
|
19 |
5 |
p. e230
|
artikel
|
| 38 |
Non-Hodgkin B-cell lymphoma involving the palate
|
Di Lorenzo, Sara
|
|
2018
|
19 |
5 |
p. e275
|
artikel
|
| 39 |
Oncologists burnout in the spotlight
|
Burki, Talha Khan
|
|
2018
|
19 |
5 |
p. e238
|
artikel
|
| 40 |
Patient-reported outcomes: an essential component of oncology drug development and regulatory review
|
Basch, Ethan
|
|
2018
|
19 |
5 |
p. 595-597
|
artikel
|
| 41 |
Precision medicine in the adjuvant treatment of gastric cancer
|
Gambardella, Valentina
|
|
2018
|
19 |
5 |
p. 583-584
|
artikel
|
| 42 |
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis
|
Cheong, Jae-Ho
|
|
2018
|
19 |
5 |
p. 629-638
|
artikel
|
| 43 |
Sarcopenia and adiposity linked to overall survival
|
Gourd, Elizabeth
|
|
2018
|
19 |
5 |
p. e239
|
artikel
|
| 44 |
Short vs long course adjuvant chemotherapy for colon cancer
|
Gunjur, Ashray
|
|
2018
|
19 |
5 |
p. e236
|
artikel
|
| 45 |
TACE plus external beam radiotherapy in liver cancer
|
Das, Manjulika
|
|
2018
|
19 |
5 |
p. e231
|
artikel
|
| 46 |
Targeting EZH2 with tazemetostat
|
Makita, Shinichi
|
|
2018
|
19 |
5 |
p. 586-587
|
artikel
|
| 47 |
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|
Italiano, Antoine
|
|
2018
|
19 |
5 |
p. 649-659
|
artikel
|
| 48 |
The My Child Matters programme: effect of public–private partnerships on paediatric cancer care in low-income and middle-income countries
|
Howard, Scott C
|
|
2018
|
19 |
5 |
p. e252-e266
|
artikel
|
| 49 |
Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?
|
Weekes, Colin D
|
|
2018
|
19 |
5 |
p. 591-592
|
artikel
|
| 50 |
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
|
Rimassa, Lorenza
|
|
2018
|
19 |
5 |
p. 682-693
|
artikel
|
| 51 |
Treatment toxicity in endometrial cancer: can we identify and manage it better?
|
Katz, Matthew S
|
|
2018
|
19 |
5 |
p. 602
|
artikel
|
| 52 |
Venetoclax plus rituximab for chronic lymphocytic leukaemia
|
Stirrups, Robert
|
|
2018
|
19 |
5 |
p. e233
|
artikel
|
Tijdschrift beschrijving